Citas bibligráficas
Vásquez, A., (2021). El impacto del derecho de patentes de productos farmacéuticos en la salud pública en el Perú [Pontificia Universidad Católica del Perú]. http://hdl.handle.net/20.500.12404/18575
Vásquez, A., El impacto del derecho de patentes de productos farmacéuticos en la salud pública en el Perú []. PE: Pontificia Universidad Católica del Perú; 2021. http://hdl.handle.net/20.500.12404/18575
@misc{renati/528940,
title = "El impacto del derecho de patentes de productos farmacéuticos en la salud pública en el Perú",
author = "Vásquez Tineo, Andrea Antoanné",
publisher = "Pontificia Universidad Católica del Perú",
year = "2021"
}
The introduction of patents to protect pharmaceutical products (1991) has reduced the access of the population, with limited economic resources, to medicines. This measure was taken at the regional level and is progressively strengthened through the signing of treaties such as the TLC that Peru has been signing. However, the biggest problem facing public health is the abuse of patent domain of patents, which further reduces the possibility of accessing medicines. This is because, by increasing the duration of the patent monopoly, medicines maintain very high prices for more than 20 years. Faced with this constant conflict between: the exclusive rights of patents on new drugs and the need of the population to access essential drugs, this work aims to show that we do not have a clear regulation on patent law that makes compatible with the right to health, since, although there are flexibility mechanisms generated in the patent system itself at the international level, at the internal level we need to establish more concrete laws and reinforce state agencies (Indecopi). In the same way, I will show the new problems surrounding the current COVID-19 pandemic as this great impact motivates us to rethink the future of exploitation monopolies in areas as important as health of people.
Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons